Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Kleber, ME; Grammer, TB; Kassner, U; Silbernagel, G; März, W.
Dusty punch cards and an eternal enigma: high-density lipoproteins and atherosclerosis.
Drugs. 2014; 74(5):513-520
Doi: 10.1007/s40265-014-0189-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
März Winfried
- Co-Autor*innen der Med Uni Graz
-
Silbernagel Günther
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Epidemiological, clinical, and experimental evidence has accumulated during the last decades suggesting that high-density lipoproteins (HDLs) may protect from atherosclerosis and its clinical consequences. However, more than 55 years after the first description of the link between HDL and heart attacks, many facets of the biochemistry, function, and clinical significance of HDL remain enigmatic. This applies particularly to the completely unexpected results that became available from some recent clinical trials of nicotinic acid and of inhibitors of cholesteryl ester transfer protein (CETP). The concept that raising HDL cholesterol by pharmacological means would decrease the risk of vascular disease has therefore been challenged.
- Find related publications in this database (using NLM MeSH Indexing)
-
Animals -
-
Atherosclerosis - blood Atherosclerosis - prevention & control
-
Cholesterol Ester Transfer Proteins - antagonists & inhibitors
-
Cholesterol, HDL - blood Cholesterol, HDL - drug effects
-
Humans -
-
Myocardial Infarction - blood
-
Niacin - pharmacology